Did you see the headline for ARIA on the same day? "ARIAD Pharmaceuticals (ARIA) Showing Signs Of Perilous Reversal Today"
It seems that someone is desperate to be right... Post the same headline for 25 pharmaceuticals and you'll get one of them right. Maybe...
Roche would have to make an offer with the other contracts in mind. Personally, I don't think a takeover bid is likely at this point because of that. They would not to be able to suck up the others 100%. The best they could do is buy the program along with cabo; but, I don't see why that would be in the interest of EXEL unless finances became too strained for their cabo trials and/or institutional investors become too weary.
It's still gong to be 6-12 months for FDA approval which is perfect for me since I'd rather have 15% federal tax on this than 40% tax.
What was the milestone payment for phase III achieving primary endpoint?
What is the milestone payment for FDA approval?
Would they really need an offering now? I'm doubting it.
Because cobimetinib met primary endpoint and they're filling with the FDA which upon approval makes this company worth at least $5.
For a doctor to use it off label would put the doctor at significant risk considering the patient is likely to die. Doing something out of common procedure and under FDA guides, would be a job killer.
I like how they equated the open to close of the previous day to the open of today.
Don't bet the farm on EXEL. IMO, they have $5 in the pocket. $25 on a good day.
Breast cancer is huge. Multibillion off the top. EXEL has to piecemeal a Billion let alone a few billion. Though, with their various trials, they could but it would not be overnight.
Though, it's possible that a short squeeze shoots us past a rational realm. It might be worth to sell and repurchase after the volume drops.
It all happened from 3:20 to 4:00 with an potentially unrelated block at 2:49.
I'm suspicious of automated trading picking a trend here. It was coming to the 4th day closing positive.
He went long with the report of meeting primary endpoint and intention to file.
I can't believe that she wants to pay interest to the banks that maintain excess reserves!
There will be a loud sucking sounds as all the capital dries up in this country as the banks simply put their money in reserve to get a share of the newly printed currency that'll never see the light of day.
I think that "news" organizations such has the Montley Fool should be subject to SEC rules and guidelines if they "own" positions in what they're covering or analyzing.
I for one was curious as to the structure of peoples thoughts on it. It started with an article saying Roche should buy EXEL by an author who I felt lacked a story with substance.
However just as a CEO would have a 1-2 year, 5 year, and 10 year plan based on possible outcomes of each program, deal, contract, and attempt at securing financing, an investor should have the options on the table of possible outcomes.
If someone has been shorting the stock and they become aware that there may be talk of buyout based on good news, they might want to move to a long position. A person trading on the gaps may take a longer position if they think they might not be able to buy lower if they sell at a given time they've become accustomed to.
If the CEO is worth their salt, that option has been hashed out and they have a number for consideration or not if they would entertain an offer. Regardless of what I think, you think or the nut job that sees a conspiratorial pump and dump in asking the question, investors have the right to question the avenues that may influence their investment decision.
The biggest key to figuring out the nut jobs here is finding the ones that believe what you say on this forum influences the ticker price.